FUTURES EXPO SERIES
Key capabilities
> Rapid , accurate diagnosis of pathogens using Nanocircle CRISPR detection
> Novel biosensors detecting pathogens and other organisms by their genes
> Compatible with test strips , sensing devices , and automated sensing systems
Differentiators
> Patent-protected NanoCirclesbased gene detection
> End-user friendly replacement for the current gold-standard method , i . e . PCR
> Established institutional partnerships with the Department of Defence , and a range of industry partners and end-users
Key customers
> DF in the field of mass testing for infectious agents
> Government instrumentalities in charge of Australian biosecurity
> Human and veterinary health authorities and relevant industry
Goldys Biosensor Research Group
Pioneering the development of non-invasive biosensors and diagnostics using cutting-edge NanoCircle CRISPR detection
Research Group
Rapid and accurate diagnosis is crucial to prevent infection spread in Defence environments , such as military vessels , field hospitals , quarantine at military bases , and borders . Rapid Infection Tests ( RATs ), with ~ 30 % false negatives in asymptomatic individuals , are insufficiently sensitive , while PCR tests are slow and costly for mass screening at entry points . This inability to rapidly identify infectious individuals hinders outbreak control and exacerbates disease transmission .
The Goldys ’ Biosensor team develops NanoCircle technology , offering tests as accurate as lab-based PCR but with rapid , on-the-spot detection . It collaborates with Key partnerships
> Partnership with ADF within CADRE
OCE > Recipients of a CRC-P funding > Supported by ARC , NHMRC and other agencies
unsw . to / arc-leadership
commercial partners and Defence to establish a new standard for scalable infection diagnostics , which are also relevant for food industry , agriculture , and biosafety management .
NanoCircle technology could expedite rapid response to emerging pathogens . Its industrial and clinical rollout in Australia aims to leverage emerging infrastructure for RNA vaccine production .
14 •